Rac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest forms of cancer, with a distinct extracellular matrix and immunosuppressive tumor microenvironment. Therefore, there is a critical need for therapies that simultaneously target metastatic cancer cells and immunosuppressive cells such as tumor associat...